Plexision102 Jan, 2021Business
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision�s CLIA-certified, central laboratory in Pittsburgh.
Wrapifai
Signature Pool Care
Mcneil Dohn
Cowan Healy
F168
Sommer Langballe
Swain Brantley
Langley Mohr
Moon Horner
Meadows Saunders